Finding the right partner is not only a problem that haunts many startup companies. It might also be one of the major limitations of using protein capture arrays to profile hundreds of markers in parallel. That’s because the numerous detection antibodies could crossreact with the wrong partners — a common problem, at least according to Nanotype, a startup company based near Munich.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.